Endocrinology, Vol 137, 410-417, Copyright © 1996 by Endocrine Society

ARTICLES

Tumorigenic and mitogenic capacities are reduced in transfected fibroblasts expressing mutant insulin-like growth factor (IGF)-I receptors. The role of tyrosine residues 1250, 1251, and 1316 in the carboxy-terminus of the IGF-I receptor

VA Blakesley, T Kalebic, LJ Helman, B Stannard, TN Faria, CT Roberts Jr and D LeRoith
Section on Molecular and Cellular Physiology, Diabetes Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland 20892, USA.

Regulation of ligand-mediated signal transduction through transmembrane tyrosine kinase growth factor receptors involves phosphorylation of tyrosine residues in the intracellular domain of the receptor. The insulin-like growth factor-I (IGF-I) receptor contains three tyrosine residues in the carboxy-terminal domain at positions 1250, 1251, and 1316. Of these, only the tyrosine at position 1316 is conserved in the homologous position of the insulin receptor. Mutational analysis was used to study the role of these tyrosines in specific outcomes of IGF-I- mediated signal transduction. Mutations in the human IGF-I receptor were either replacement of tyrosines 1250 and 1251 with phenylalanine and histidine (yyFH), respectively, or replacement of the conserved distal tyrosine (position 1316) with phenylalanine (yCF). The yyFH mutation results in an IGF-I receptor with the amino acids found in the homologous position of the human insulin receptor. Cells overexpressing mutated IGF-I receptors were compared with cells expressing only endogenous IGF-I receptors or overexpressing wild-type IGF-I receptors. The ability of yyFH mutant IGF-I receptors to autophosphorylate the beta-subunit or phosphorylate insulin receptor substrate-1 was not significantly different from wild-type type IGF-I receptors. However, one or both of the proximal tyrosine residues (positions 1250 and 1251) in the carboxy-terminus of the IGF-I receptor are essential for IGF-I- stimulation of mitogenic and tumorigenic pathways. IGF-I-induced mitogenesis, measured as thymidine incorporation and cellular proliferation, was abrogated in cells overexpressing mutant IGF-I receptors with replacement of the proximal double tyrosines (positions 1250 and 1251). Fibroblasts expressing this mutant IGF-I receptor formed fewer tumors than the negative control cells, whereas cells expressing wild-type IGF-I receptors formed large tumors in all recipient mice injected. Conversely, cells expressing mutant IGF-I receptors with only the conserved distal tyrosine (position 1316) replaced had slightly reduced IGF-I-stimulated beta-subunit autophosphorylation, thymidine incorporation, and cellular proliferation when compared with cells expressing wild-type receptors. Phosphorylation of insulin receptor substrate-1 by the yCF mutant receptors was not impaired. Despite the ability of these mutant receptors to stimulate mitogenic growth, fibroblasts expressing this mutant receptor were also incapable of forming tumors in recipient nude mice. The distal tyrosine (position 1316) of the IGF-I receptor is crucial for tumor formation but is not essential for IGF-I stimulated mitogenesis. Thus, the tyrosine moieties in the carboxy-terminus of the IGF-I receptor participate in the signal transduction pathways that affect the mitogenic and tumorigenic potentials of cells expressing mutant IGF-I receptors.

This article has been cited by other articles:

				M. Leahy, A. Lyons, D. Krause, and R. O'Connor Impaired Shc, Ras, and MAPK Activation but Normal Akt Activation in FL5.12 Cells Expressing an Insulin-like Growth Factor I Receptor Mutated at Tyrosines 1250 and 1251 J. Biol. Chem., April 30, 2004; 279(18): 18306 - 18313. [Abstract] [Full Text] [PDF]

				C. Mulligan, J. Rochford, G. Denyer, R. Stephens, G. Yeo, T. Freeman, K. Siddle, and S. O'Rahilly Microarray Analysis of Insulin and Insulin-like Growth Factor-1 (IGF-1) Receptor Signaling Reveals the Selective Up-regulation of the Mitogen Heparin-binding EGF-like Growth Factor by IGF-1 J. Biol. Chem., November 1, 2002; 277(45): 42480 - 42487. [Abstract] [Full Text] [PDF]

				M. Navarro and R. Baserga Limited Redundancy of Survival Signals from the Type 1 Insulin-Like Growth Factor Receptor Endocrinology, March 1, 2001; 142(3): 1073 - 1081. [Abstract] [Full Text] [PDF]

				H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text]

				R. S. MacDonald The Role of Zinc in Growth and Cell Proliferation J. Nutr., May 1, 2000; 130(5): 1500S - 1508. [Abstract] [Full Text]

				A. Casamassima and E. Rozengurt Insulin-like Growth Factor I Stimulates Tyrosine Phosphorylation of p130Cas, Focal Adhesion Kinase, and Paxillin. ROLE OF PHOSPHATIDYLINOSITOL 3'-KINASE AND FORMATION OF A p130Cas·Crk COMPLEX J. Biol. Chem., October 2, 1998; 273(40): 26149 - 26156. [Abstract] [Full Text] [PDF]

				R. S. MacDonald, L. C. Wollard-Biddle, J. D. Browning,, W. H. Thornton Jr., and B. L. O'Dell Zinc Deprivation of Murine 3T3 Cells by Use of Diethylenetrinitrilopentaacetate Impairs DNA Synthesis upon Stimulation with Insulin-Like Growth Factor-I (IGF-I) J. Nutr., October 1, 1998; 128(10): 1600 - 1605. [Abstract] [Full Text]

				V. A. Blakesley, A. P. Koval, B. S. Stannard, A. Scrimgeour, and D. LeRoith Replacement of Tyrosine 1251 in the Carboxyl Terminus of the Insulin-like Growth Factor-I Receptor Disrupts the Actin Cytoskeleton and Inhibits Proliferation and Anchorage-independent Growth J. Biol. Chem., July 17, 1998; 273(29): 18411 - 18422. [Abstract] [Full Text] [PDF]

				J. G. Jackson, M. F. White, and D. Yee Insulin Receptor Substrate-1 is the Predominant Signaling Molecule Activated by Insulin-like Growth Factor-I, Insulin, and Interleukin-4 in Estrogen Receptor-positive Human Breast Cancer Cells J. Biol. Chem., April 17, 1998; 273(16): 9994 - 10003. [Abstract] [Full Text] [PDF]

				W. Zhang, W. H. Thornton Jr., and R. S. MacDonald Insulin-Like Growth Factor-I and II Receptor Expression in Rat Colon Mucosa Are Affected by Dietary Lipid Intake J. Nutr., February 1, 1998; 128(2): 158 - 165. [Abstract] [Full Text]

				R. Foncea, M. Andersson, A. Ketterman, V. Blakesley, M. Sapag-Hagar, P. H. Sugden, D. LeRoith, and S. Lavandero Insulin-like Growth Factor-I Rapidly Activates Multiple Signal Transduction Pathways in Cultured Rat Cardiac Myocytes J. Biol. Chem., August 1, 1997; 272(31): 19115 - 19124. [Abstract] [Full Text] [PDF]

				D. L. Esposito, V. A. Blakesley, A. P. Koval, A. G. Scrimgeour, and D. LeRoith Tyrosine Residues in the C-Terminal Domain of the Insulin-Like Growth Factor-I Receptor Mediate Mitogenic and Tumorigenic Signals Endocrinology, July 1, 1997; 138(7): 2979 - 2988. [Abstract] [Full Text] [PDF]

				A. G. Scrimgeour, V. A. Blakesley, B. S. Stannard, and D. LeRoith Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase Pathways Are Not Sufficient for Insulin-Like Growth Factor I-Induced Mitogenesis and Tumorigenesis Endocrinology, June 1, 1997; 138(6): 2552 - 2558. [Abstract] [Full Text] [PDF]

				S. R. Plymate, V. L. Bae, L. Maddison, L. S. Quinn, and J. L. Ware Reexpression of the Type 1 Insulin-Like Growth Factor Receptor Inhibits the Malignant Phenotype of Simian Virus 40 T Antigen Immortalized Human Prostate Epithelial Cells Endocrinology, April 1, 1997; 138(4): 1728 - 1735. [Abstract] [Full Text] [PDF]

				P. Brodt, L. Fallavollita, A.-M. Khatib, A. A. Samani, and D. Zhang Cooperative Regulation of the Invasive and Metastatic Phenotypes by Different Domains of the Type I Insulin-like Growth Factor Receptor beta Subunit J. Biol. Chem., August 31, 2001; 276(36): 33608 - 33615. [Abstract] [Full Text] [PDF]